Туберкулез и болезни лёгких (Jun 2022)

DprE1 inhibitors – a prospective target for development of antituberculosis drugs

  • A. V. Kukurika

DOI
https://doi.org/10.21292/2075-1230-2022-100-5-64-70
Journal volume & issue
Vol. 100, no. 5
pp. 64 – 70

Abstract

Read online

The article reviews and analyzes 63 scientific publications devoted to new classes of antituberculosis drugs – DprE1 inhibitors. Currently, compounds BTZ-043, PBTZ-169 (makozinone), TBA-7371 and OPC-167832 are tested at different stages of clinical trials. DprE1 inhibitors are promising drugs with antituberculosis activity, which requires further clinical trials.

Keywords